Eric J. Ende - 29 Jul 2025 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Director
Signature
/s/ Jerad G. Seurer, as Attorney-in-Fact
Issuer symbol
AVDL
Transactions as of
29 Jul 2025
Net transactions value
$0
Form type
4
Filing time
31 Jul 2025, 16:07:44 UTC
Previous filing
14 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ende Eric J Director C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND /s/ Jerad G. Seurer, as Attorney-in-Fact 31 Jul 2025 0001494386

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVDL Ordinary Shares Award $0 +11,000 +5.3% $0.000000 219,900 29 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +11,000 $0.000000 11,000 29 Jul 2025 Ordinary Shares 11,000 $10.83 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.
F2 The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.